Delaware District Court Rules in Favor of Acadia on Formulation Patent Construction (Markman) Claims Regarding NUPLAZID® (pimavanserin)
December 13 2023 - 9:24PM
Business Wire
- This is the second patent ruling issued today
from the Court in favor of Acadia
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that
the U.S. District Court for the District of Delaware has issued a
Claim Construction Order in favor of Acadia regarding its ‘721
formulation patent for NUPLAZID® (pimavanserin), Acadia’s drug for
the treatment of Parkinson’s Disease Psychosis. In today’s Order,
the Court ruled in favor of Acadia on all of the disputed claim
construction points.
In the Order, the Court adopted Acadia’s interpretation of key
disputed terms of the patent. Acadia believes that the Court’s
interpretations affirm the strength of the patent. As a result of
today’s order, a claims construction hearing (also referred to as a
“Markman” hearing), which had been scheduled for December 19, 2023,
has been cancelled by the Court. The case remains scheduled for
trial in December 2024.
This was the second ruling issued today by the Court pertaining
to Acadia’s patents covering NUPLAZID. Earlier today, in a separate
litigation, the Court granted summary judgment to Acadia,
confirming validity of Acadia’s ‘740 composition of matter
patent.
“We are pleased to announce a second positive ruling today from
the U.S. District Court for the District of Delaware, both of which
underscore the strength of our NUPLAZID patent estate, including
patents running into 2038,” said Steve Davis, President and Chief
Executive Officer. “Establishing claims construction is an
important milestone in patent litigation. We look forward to
proceeding with the remainder of our formulation patent case.”
The formulation patent that is the subject of today’s claims
construction ruling is scheduled to expire in 2038. In addition,
Acadia has a method of use patent on the 10mg tablet of NUPLAZID
that runs to 2037 and a NUPLAZID composition of matter patent,
which was the subject of today’s earlier ruling, that runs to
2030.
About NUPLAZID® (pimavanserin)
Pimavanserin is a selective serotonin inverse agonist and
antagonist preferentially targeting 5-HT2A receptors. These
receptors are thought to play an important role in neuropsychiatric
disorders. In vitro, pimavanserin demonstrated no appreciable
binding affinity for dopamine (including D2), histamine,
muscarinic, or adrenergic receptors. Pimavanserin was approved for
the treatment of hallucinations and delusions associated with
Parkinson’s disease psychosis by the U.S. Food and Drug
Administration in April 2016 under the trade name NUPLAZID. In
addition, Acadia is developing pimavanserin as a potential
treatment for the negative symptoms of schizophrenia.
About Acadia Pharmaceuticals
Acadia is advancing breakthroughs in neuroscience to elevate
life. For 30 years we have been working at the forefront of
healthcare to bring vital solutions to people who need them most.
We developed and commercialized the first and only approved
therapies for hallucinations and delusions associated with
Parkinson’s disease psychosis and for the treatment of Rett
syndrome. Our clinical-stage development efforts are focused on
treating the negative symptoms of schizophrenia, Prader-Willi
syndrome, Alzheimer’s disease psychosis and neuropsychiatric
symptoms in central nervous system disorders. For more information,
visit us at www.acadia.com and follow us on LinkedIn and
Twitter.
Forward-Looking Statements
Statements in this press release that are not strictly
historical in nature are forward-looking statements. These
statements include but are not limited to statements regarding the
timing of future events. These statements are only predictions
based on current information and expectations and involve a number
of risks and uncertainties. Actual events or results may differ
materially from those projected in any of such statements due to
various factors, including the risks and uncertainties inherent in
drug development, approval and commercialization. For a discussion
of these and other factors, please refer to Acadia’s annual report
on Form 10-K for the year ended December 31, 2022, as well as
Acadia’s subsequent filings with the Securities and Exchange
Commission. You are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date hereof.
This caution is made under the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995. All
forward-looking statements are qualified in their entirety by this
cautionary statement and Acadia undertakes no obligation to revise
or update this press release to reflect events or circumstances
after the date hereof, except as required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231213441201/en/
Media Contact: Acadia Pharmaceuticals Inc. Deb Kazenelson (818)
395-3043 media@acadia-pharm.com
Investor Contact: Acadia Pharmaceuticals Inc. Al Kildani (858)
261-2872 ir@acadia-pharm.com
Acadia Pharmaceuticals Inc. Jessica Tieszen (858) 261-2950
ir@acadia-pharm.com
Acadia Pharmaceuticals (NASDAQ:ACAD)
Historical Stock Chart
From Apr 2024 to May 2024
Acadia Pharmaceuticals (NASDAQ:ACAD)
Historical Stock Chart
From May 2023 to May 2024